Sinovac maintains lead as pioneering hand, foot and mouth vaccine moves to Phase III
This article was originally published in Scrip
Executive Summary
Based on positive top-line results from a Phase II trial, Sinovac Biotech is preparing to take its vaccine for a serious form of human hand, foot and mouth disease (HFMD) into a multi-centre Phase III programme in China over the next few months.